These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38424699)

  • 1. Anti-resorptive therapy and MRONJ. A survey of the Italian Society of Periodontology and Implantology.
    Landi L; Oteri G; Barbato L; Discepoli N; Carrassi AM; Rigoni M; Cairo F; Cavalcanti R; Crea A; Gianserra R; Sforza NM
    Oral Dis; 2024 Oct; 30(7):4528-4537. PubMed ID: 38424699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-resorptive therapy in the osteometabolic patient affected by periodontitis. A joint position paper of the Italian Society of Orthopaedics and Traumatology (SIOT) and the Italian Society of Periodontology and Implantology (SIdP).
    Landi L; Leali PT; Barbato L; Carrassi AM; Discepoli N; Muti PCM; Oteri G; Rigoni M; Romanini E; Ruggiero C; Tarantino U; Varoni E; Sforza NM; Brandi ML
    J Orthop Traumatol; 2023 Jul; 24(1):36. PubMed ID: 37453950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020.
    Campisi G; Mauceri R; Bertoldo F; Bettini G; Biasotto M; Colella G; Consolo U; Di Fede O; Favia G; Fusco V; Gabriele M; Lo Casto A; Lo Muzio L; Marcianò A; Mascitti M; Meleti M; Mignogna MD; Oteri G; Panzarella V; Romeo U; Santarelli A; Vescovi P; Marchetti C; Bedogni A
    Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32824826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals.
    Miranda-Silva W; Montezuma MA; Benites BM; Bruno JS; Fonseca FP; Fregnani ER
    Support Care Cancer; 2020 Nov; 28(11):5397-5404. PubMed ID: 32144584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.
    Matsumoto A; Sasaki M; Schmelzeisen R; Oyama Y; Mori Y; Voss PJ
    Clin Oral Investig; 2017 Jan; 21(1):127-134. PubMed ID: 26924135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Across-sectional survey on medication-related osteonecrosis of the jaws' knowledge and awareness in a sample of dental society.
    Al-Samman AA; Al-Ani RS
    J Craniomaxillofac Surg; 2019 Jun; 47(6):926-931. PubMed ID: 30952475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key insights into antiresorptive drug use and osteonecrosis in osteoporotic patients undergoing tooth extractions: A clinical and CBCT assessment.
    Moreno-Rabié C; Fontenele RC; Oliveira-Santos N; Nogueira-Reis F; Van den Wyngaert T; Jacobs R
    Osteoporos Int; 2024 Aug; 35(8):1431-1440. PubMed ID: 38767743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts.
    Zhao N; Li QX; Wang YF; Qiao Q; Huang HY; Guo CB; Guo YX
    BMC Oral Health; 2023 May; 23(1):330. PubMed ID: 37245004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of leukocyte and platelet-rich fibrin in the prevention of medication-related osteonecrosis of the jaw, in patients requiring dental extractions: an observational study.
    Besi E; Pitros P
    Oral Maxillofac Surg; 2024 Jun; 28(2):785-793. PubMed ID: 38182917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-dimensional clinical assessment for MRONJ risk in oncologic patients following tooth extractions.
    Moreno Rabie C; Cavalcante Fontenele R; Oliveira Santos N; Nogueira Reis F; Van den Wyngaert T; Jacobs R
    Dentomaxillofac Radiol; 2023 Nov; 52(8):20230238. PubMed ID: 37874081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
    Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
    PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperation between physicians and dentists for osteonecrosis of the jaw: a 2022 Japanese survey.
    Taguchi A; Hagino H; Inoue D; Endo N; Society JO
    J Bone Miner Metab; 2023 Nov; 41(6):829-837. PubMed ID: 37516668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Awareness About Medication-Related Osteonecrosis of the Jaw Among Dental Professionals: A Multicentre Study.
    Patil V; Acharya S; Vineetha R; Nikhil K
    Oral Health Prev Dent; 2020 Jul; 18(3):505-509. PubMed ID: 32016175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors associated to Medication-Related Osteo Necrosis of the Jaw (MRONJ) in patients with osteoporosis after tooth extractions. A 12-months observational cohort study.
    Cuozzo A; Iorio-Siciliano V; Vaia E; Mauriello L; Blasi A; Ramaglia L
    J Stomatol Oral Maxillofac Surg; 2022 Nov; 123(6):616-621. PubMed ID: 35609780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis?
    Giovannacci I; Meleti M; Manfredi M; Mortellaro C; Greco Lucchina A; Bonanini M; Vescovi P
    J Craniofac Surg; 2016 May; 27(3):697-701. PubMed ID: 27092912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral bisphosphonate-induced osteonecrosis complications in patients undergoing tooth extraction: a systematic review and literature updates.
    Dioguardi M; Di Cosola M; Copelli C; Cantore S; Quarta C; Nitsch G; Sovereto D; Spirito F; Caloro GA; Cazzolla AP; Aiuto R; Cascardi E; Greco Lucchina A; Lo Muzio L; Ballini A; Mastrangelo F
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(13):6359-6373. PubMed ID: 37458653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?
    Ueda N; Nakashima C; Aoki K; Shimotsuji H; Nakaue K; Yoshioka H; Kurokawa S; Imai Y; Kirita T
    Clin Oral Investig; 2021 May; 25(5):3087-3093. PubMed ID: 33057886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
    Hasegawa T; Kawakita A; Ueda N; Funahara R; Tachibana A; Kobayashi M; Kondou E; Takeda D; Kojima Y; Sato S; Yanamoto S; Komatsubara H; Umeda M; Kirita T; Kurita H; Shibuya Y; Komori T;
    Osteoporos Int; 2017 Aug; 28(8):2465-2473. PubMed ID: 28451732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O; Peter JU
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012432. PubMed ID: 35866376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.